Literature DB >> 33580358

Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals.

Nic Gillings1, Olaug Hjelstuen2, Jim Ballinger3, Martin Behe4, Clemens Decristoforo5, Philip Elsinga6, Valentina Ferrari7, Petra Kolenc Peitl8, Jacek Koziorowski9, Peter Laverman10, Thomas L Mindt11, Oliver Neels12, Meltem Ocak13, Marianne Patt14, Sergio Todde15.   

Abstract

This guideline on current good radiopharmacy practice (cGRPP) for small-scale preparation of radiopharmaceuticals represents the view of the Radiopharmacy Committee of the European Association of Nuclear Medicine (EANM). The guideline is laid out in the format of the EU Good Manufacturing Practice (GMP) guidelines as defined in EudraLex volume 4. It is intended for non-commercial sites such as hospital radiopharmacies, nuclear medicine departments, research PET centres and in general any healthcare establishments. In the first section, general aspects which are applicable to all levels of operations are discussed. The second section discusses the preparation of small-scale radiopharmaceuticals (SSRP) using licensed generators and kits. Finally, the third section goes into the more complex preparation of SSRP from non-licensed starting materials, often requiring a purification step and sterile filtration. The intention is that the guideline will assist radiopharmacies in the preparation of diagnostic and therapeutic SSRP's safe for human administration.

Entities:  

Keywords:  GMP; Radiopharmaceuticals; Radiopharmacy; cGRPP

Year:  2021        PMID: 33580358     DOI: 10.1186/s41181-021-00123-2

Source DB:  PubMed          Journal:  EJNMMI Radiopharm Chem        ISSN: 2365-421X


  12 in total

Review 1.  Good practices for 68Ga radiopharmaceutical production.

Authors:  Bryce J B Nelson; Jan D Andersson; Frank Wuest; Sarah Spreckelmeyer
Journal:  EJNMMI Radiopharm Chem       Date:  2022-10-22

2.  Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients.

Authors:  Youssef Chahid; Xinbo Qiu; Ewoudt M W van de Garde; Hein J Verberne; Jan Booij
Journal:  EJNMMI Res       Date:  2021-06-09       Impact factor: 3.138

Review 3.  Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?

Authors:  Nicolas Lepareur
Journal:  Front Med (Lausanne)       Date:  2022-02-10

4.  Experience with radiopharmacy information system.

Authors:  Jesús Luis Gómez Perales
Journal:  EJNMMI Radiopharm Chem       Date:  2022-07-19

5.  A Specific HPLC Method to Determine Residual HEPES in [68Ga]Ga-Radiopharmaceuticals: Development and Validation.

Authors:  Silvia Migliari; Maura Scarlattei; Giorgio Baldari; Claudia Silva; Livia Ruffini
Journal:  Molecules       Date:  2022-07-13       Impact factor: 4.927

6.  EANM guideline on quality risk management for radiopharmaceuticals.

Authors:  Nic Gillings; Olaug Hjelstuen; Martin Behe; Clemens Decristoforo; Philip H Elsinga; Valentina Ferrari; Oliver C Kiss; Petra Kolenc; Jacek Koziorowski; Peter Laverman; Thomas L Mindt; Meltem Ocak; Marianne Patt; Sergio Todde; Almut Walte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

7.  Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Arnoldo Piccardo; Nathalie L Albert; Lise Borgwardt; Frederic H Fahey; Darren Hargrave; Norbert Galldiks; Nina Jehanno; Lars Kurch; Ian Law; Ruth Lim; Egesta Lopci; Lisbeth Marner; Giovanni Morana; Tina Young Poussaint; Victor J Seghers; Barry L Shulkin; Katherine E Warren; Tatjana Traub-Weidinger; Pietro Zucchetta
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-05-10       Impact factor: 10.057

8.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

9.  Synthesis, Physicochemical and Biological Study of Gallium-68- and Lutetium-177-Labeled VEGF-A165/NRP-1 Complex Inhibitors Based on Peptide A7R and Branched Peptidomimetic.

Authors:  Katarzyna Masłowska; Ewa Witkowska; Dagmara Tymecka; Paweł Krzysztof Halik; Aleksandra Misicka; Ewa Gniazdowska
Journal:  Pharmaceutics       Date:  2022-01-01       Impact factor: 6.321

Review 10.  Strategic, feasibility, economic, and cultural aspects of phase 0 approaches: Is it time to change the drug development process in order to increase productivity?

Authors:  Tal Burt; Ad F Roffel; Oliver Langer; Kirsten Anderson; Joseph DiMasi
Journal:  Clin Transl Sci       Date:  2022-04-21       Impact factor: 4.438

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.